GT Biopharma, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Effective March 2, 2022, the Registrant appointed Michael Breen as the Registrant’s Interim Chief Executive Officer with an increase in his annual base compensation to $515,000.
Gregory Berk, M.D. ceased serving as the Registrant’s Interim Chief Executive Officer, but will continue to serve as the Registrant’s President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.
Extracted from this filing and checked against the source text.
Michael Breen was appointed as Interim Chief Executive Officer at GT Biopharma, Inc..
Effective March 2, 2022, the Registrant appointed Michael Breen as the Registrant’s Interim Chief Executive Officer with an increase in his annual base compensation to $515,000.View on SEC.gov
Gregory Berk changed role as President of Research & Development and Chief Medical Officer at GT Biopharma, Inc..
Gregory Berk, M.D. ceased serving as the Registrant’s Interim Chief Executive Officer, but will continue to serve as the Registrant’s President of Research & Development and Chief Medical Officer, with a cost-of-living increase in his annual base compensation to $437,750.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.